Health, pharma & the biotechnology mission
India's health, pharmaceutical and biotechnology ecosystem for UPSC: BioE3 policy, vaccine platforms, gene therapy, regulators, and the missions powering the bioeconomy.
From Vaccine Maitri to BioE3
India frames biotechnology as a strategic sector. The Department of Biotechnology (DBT), created in 1986 under the Ministry of Science and Technology, is the apex policy body, supported by its public-sector enterprise BIRAC (Biotechnology Industry Research Assistance Council, 2012), which de-risks startup innovation. The flagship vision is the BioE3 Policy (‘Biotechnology for Economy, Environment and Employment’), approved by the Union Cabinet on 24 August 2024. BioE3 targets high-performance biomanufacturing across six themes: bio-based chemicals and enzymes; functional foods and smart proteins; precision biotherapeutics; climate-resilient agriculture; carbon capture and utilisation; and marine and space biotechnology. It establishes Biomanufacturing and Bio-AI hubs and Biofoundries, and explicitly aims to expand India's bioeconomy, which the Economic Survey and DBT report grew from about USD 10 billion (2014) to over USD 150 billion (2024), with a target of USD 300 billion by 2030.
Mission COVID Suraksha and the platform legacy
India's vaccine capability is its global calling card. Covaxin (BBV152), an inactivated whole-virion vaccine, was developed by Bharat Biotech with the ICMR–National Institute of Virology, Pune, and received WHO Emergency Use Listing on 3 November 2021. Covishield was the Serum Institute of India's licensed manufacture of the Oxford–AstraZeneca adenoviral-vector vaccine. ZyCoV-D (Zydus Cadila), cleared by the DCGI in August 2021, was the world's first approved plasmid DNA vaccine and India's first needle-free (jet-injector) vaccine. CORBEVAX (Biological E) was a protein sub-unit vaccine. iNCOVACC became the world's first intranasal COVID vaccine to receive approval (2022). These were financed partly through Mission COVID Suraksha under the Atmanirbhar Bharat 3.0 package.
Regulators and the gene-therapy frontier
The drug regulator is the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), operating under the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019. For genetically engineered organisms and products, the Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment (per the 1989 Rules of the Environment Protection Act, 1986) is the apex approver. In October 2023 GEAC recommended environmental release of DMH-11, India's first transgenic (GM) mustard hybrid — a recurring Prelims hook. On the cutting edge, in October 2024 the CDSCO approved NexCAR19, India's first indigenously developed CAR-T cell therapy (developed by IIT Bombay, Tata Memorial Centre and ImmunoACT) for B-cell cancers, dramatically cheaper than imported equivalents. India is also advancing gene therapy for sickle cell disease, aligned with the National Sickle Cell Anaemia Elimination Mission (2023, target 2047).
